论文部分内容阅读
目的:研究硫唑嘌呤联合英夫利昔单抗治疗克罗恩病的临床效果。方法:对我院治疗的克罗恩病患者210例为研究对象,平均分为两组,每组70例患者。英夫利昔单独治疗组的患者给予常规治疗;联合治疗的观察组使用两种药物同时联合治疗的措施,口服硫唑嘌呤2.5毫克/(千克·天),并给予静脉注射英夫利昔单抗试剂5毫克/(千克·天),分别于患者治疗首日,第2周,一个与人及以后每隔两个月进行相同剂量的治疗。结果:与对照治疗对比,联合治疗的观察组的患者白蛋白和血清总蛋白的数据升高,患者的病理表现相对减弱,患者的黏膜愈合率较高。结论:采用硫唑嘌呤联合英夫利昔单抗试剂治疗克罗恩病,可以减弱患者的临床不适症状,提高患者的临床治疗的有效率,值得在临床上推广。
Objective: To investigate the clinical effect of azathioprine combined with infliximab in the treatment of Crohn’s disease. Methods: A total of 210 Crohn’s disease patients treated in our hospital were divided into two groups, 70 patients in each group. Patients in the infliximab-alone treatment group were given conventional treatment; the combination treatment observation group was treated with 2.5 mg / (kg · day) of azathioprine orally and an IV infliximab was given intravenously 5 mg / (kg · day), respectively, the first day of treatment, the first two weeks, one with the same dose every two months and thereafter. Results: Compared with the control treatment, the data of albumin and serum total protein in the combined treatment group increased, the pathological findings of the patients were relatively weakened, and the mucosal healing rate of the patients was higher. Conclusion: The use of azathioprine combined with infliximab treatment of Crohn’s disease can reduce the clinical symptoms of patients and improve the clinical treatment of patients with efficiency, it is worth in the clinical promotion.